Source: Cision

Janssen Research & Development: Diamyd Medical signs agreement with Janssen R&D, JDRF and UAB regarding ongoing GABA/GAD-trial

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced that it has signed an agreement with Janssen Research & Development, the Juvenile Diabetes Research Foundation (JDRF) and the University of Alabama at Birmingham regarding the ongoing clinical trial "Effect of GABA or Combination GABA/GAD on the Progression of Type 1 Diabetes Mellitus in Children". The agreement entails that Janssen Research & Development and JDRF will support the trial with approximately USD 600 000 to be used to study GABA-biomarkers and to increase the number of patients in the trial. "The

Read full article »
Est. Annual Revenue
$5.0-25M
Agree?
Est. Employees
25-100
Agree?